valrubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 2805 56124-62-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • valrubicin
  • N-Trifluoroacetyladriamycin 14-valerate
  • valstar
  • N-Trifluoroacetyldoxorubicin 14-valerate
  • AD-32
  • Molecular weight: 723.65
  • Formula: C34H36F3NO13
  • CLOGP: 3.19
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 5
  • TPSA: 215.22
  • ALOGS: -4.35
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 25, 1998 FDA ENDO PHARM

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bladder instillation procedure 119.69 76.73 10 64 0 29574453
Urge incontinence 89.72 76.73 11 63 491 29573962

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bladder instillation procedure 140.48 86.43 11 62 0 64498659
Urge incontinence 101.07 86.43 12 61 924 64497735

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Malignant tumor of urinary bladder indication 399326009 DOID:11054
Urinary tract infectious disease contraindication 68566005
Bladder muscle dysfunction - overactive contraindication 236633002
Rupture of bladder contraindication 251925007
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001
Bladder Surgery contraindication
Small Capacity Bladder contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.85 acidic
pKa2 9.66 acidic
pKa3 10.37 acidic
pKa4 12.86 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR WOMBAT-PK CHEMBL

External reference:

IDSource
4021144 VUID
N0000148597 NUI
D02697 KEGG_DRUG
4021144 VANDF
C0068314 UMLSCUI
CHEBI:135876 CHEBI
CHEMBL1096885 ChEMBL_ID
DB00385 DRUGBANK_ID
C016163 MESH_SUPPLEMENTAL_RECORD_UI
7750 INN_ID
2C6NUM6878 UNII
454216 PUBCHEM_CID
220725 RXNORM
11903 MMSL
327252 MMSL
7552 MMSL
d04356 MMSL
007694 NDDF
116079002 SNOMEDCT_US
387002006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Valrubicin Intravesical Solution HUMAN PRESCRIPTION DRUG LABEL 1 24201-101 SOLUTION, CONCENTRATE 40 mg INTRAVESICAL ANDA 26 sections
Valstar HUMAN PRESCRIPTION DRUG LABEL 1 67979-001 SOLUTION, CONCENTRATE 40 mg INTRAVESICAL NDA 26 sections